Ba Yi

Research areas: Basic and clinical research on gastrointestinal tumors, focusing on neoadjuvant chemotherapy before surgery, adjuvant chemotherapy after surgery, and salvage chemotherapy and targeted therapy for patients with recurrent and metastatic gastrointestinal malignancies.

Cutting-edge technologies: Led the translation of cutting-edge therapies such as CAR-T, TCR-T, and bispecific antibodies into clinical practice, promoting clinical research from "paper publication" to "truly solving clinical problems." As a principal investigator, responsible for multiple international and domestic multicenter clinical studies on gastric cancer, colorectal cancer, and pancreatic cancer.

Areas of expertise: Chemotherapy, targeted therapy, and immunotherapy for gastrointestinal tumors (esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer).

Academic Highlights and Core Values: Director of the Cancer Medical Center and Department of Medical Oncology, Chief Physician, Doctoral Supervisor, Level II Professor of the Chinese Academy of Medical Sciences and Peking Union Medical College, recipient of the National Hundred, Thousand, and Ten Thousand Talents Program, a New Century Talent of the Ministry of Education, and enjoys special allowances from the State Council. Completed postdoctoral research at the Scripps Research Institute in the United States in 2002. Former Chairman of the Cancer Supportive Treatment Professional Committee of the Chinese Anti-Cancer Association, Vice Chairman of the Cancer Clinical Chemotherapy Professional Committee, and expert of the Colorectal Cancer Group of the Medical Administration Department of the Ministry of Health. Designed, led, and participated in nearly 100 global and national multicenter clinical studies.